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Background: Assimilation of iron is essential for microbial growth. Most 
microbes synthesize and excrete low molecular weight iron chelators called 
siderophores to sequester and deliver iron by active transport processes. Spe- 
cific outer membrane proteins recognize, bind and initiate transport of species- 
selective ferric siderophore complexes. Organisms most often have specific 
receptors for multiple types of siderophores, presumably to ensure adequate 
acquisition of the iron that is essential for their growth. Conjugation of drugs to 
synthetic hydroxamate or catechol siderophore components can facilitate active 
iron-transport-mediated drug’ delivery. While resistance to the siderophore-drug 
conjugates frequently occurs by selection of mutants deficient in the correspond- 
ing siderophore-selective outer membrane receptor, the mutants are less able to 
survive under iron-deficient conditions and in viva. We anticipated that synthesis 
of mixed ligand siderophore-drug conjugates would allow active drug delivery by 
multiple iron receptor recognition and transport processes, further reducing the 
likelihood that resistant mutants would be viable. 
Results: Mixed ligand siderophore-drug conjugates were synthesized by com- 
bining hydroxamate and catechol components in a single compound that could 
chelate iron, and that also contained a covalent linkage to carbacephalosporins, 
as representative drugs. The new conjugates appear to be assimilated by multi- 
ple active iron-transport processes both in wild type microbes and in selected 
mutants that are deficient in some outer membrane iron-transport receptors. 
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Conclusions: The concept of active iron-transport-mediated drug delivery can 
now be extended to drug conjugates that can enter the cell through multiple outer 
membrane receptors. Mutants that are resistant to such conjugates should be 
severely impaired in iron uptake, and therefore particularly prone to iron starvation. 
Introduction 
Resistance to individual or even whole classes of drugs 
is emerging as a major threat to antibiotic therapy [1,2]. 
The overuse of antibiotics promotes microbial resistance, 
which can arise from changes in microbial permeability 
barriers [3] or drug-binding sites [4], or from the acquisi- 
tion of enzymes that destroy the antimicrobial agents [5]. 
Alternative drug-delivery processes have been sought to 
circumvent the problem of reduced permeability, which 
results from a limitation of passive diffusion through size- 
restricted porins. 
Most microbes assimilate physiologically essential iron 
by synthesizing and utilizing high affinity ferric ion chela- 
tors, called siderophores [6]. Proteins in the outer mem- 
brane then recognize the ferric complexes and initiate their 
active transport. The idea that conjugation of antibiotics 
to siderophores might facilitate active drug transport 
by siderophore-mediated drug delivery was therefore an 
attractive one. Indeed, there are several natural examples 
of antibiotic-containing siderophores (e.g. albomycins 
and ferrimycin A) that are taken up into bacterial cells 
via active iron-transport systems [7,8]. We previously 
reported the synthesis and antimicrobial activity of artifi- 
cial siderophore-drug conjugates (compounds 1 [9] and 2 
[lo], Fig. 1) consisting of carbacephalosporins with sepa- 
rate hydroxamic-acid-based and catechol-based sidero- 
phore components [ 11,121. As expected, biological assays 
revealed that these conjugates used different outer mem- 
brane receptor proteins to initiate entry into the cell 
[13,14]. Although strains that lack the outer membrane 
proteins that recognize and mediate uptake of compound 1 
or 2 were rapidly selected in vitro and were resistant to the 
conjugates they were originally selected with, they were 
still susceptible to the other conjugate [14], showing that 
the defect in conjugate uptake was specific for the appro- 
priate uptake system. Preliminary in U&VO studies revealed 
that the selected mutants were not pathogenic, presumably 
because the mutant lacked a full complement of iron- 
assimilation mechanisms and is therefore at a growth 
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Artificial siderophore-drug conjugates: compounds 1 [9] and 2 [lo]. 
disadvantage in serum. In addition, when both conjugates 
were used together the inhibition of microbial growth was 
more profound than when either conjugate was used alone. 
We therefore postulated that a drug conjugate that could 
be recognized by multiple siderophore-uptake systems, for 
example one containing both catechol and hydroxamate 
components, might show enhanced inhibition of microbial 
growth and minimize the development of resistance by 
selection of mutants defective in one type of siderophore 
recognition. Any strains resistant to such a drug would be 
expected to have defects in more than one iron-uptake 
system and therefore be especially prone to iron starvation. 
Here we describe the synthesis of the first mixed hydroxa- 
mate and catechol-containing siderophore-like conjugates 
of carbacephalosporins, and a preliminary study of their 
biological activity. 
Results and discussio’n 
Chemical synthesis 
We anticipated that separate coupling of protected hydrox- 
amate derivatives (compounds 5 and 6) [15], of both the 
parent carbacephem nucleus and Lorabid@ (Loracarbef) 
[16] with protected biscatechol-containing spermidine 
derivative 7 would provide a direct route to compounds 
3a and 3b (Fig. 2). Alternatively, coupling of protected 
forms of S-N-hydroxyornithyl carbacephalosporin 8a or the 
corresponding tripeptide derivative 8b [9] with 7 would 
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Synthetic pathway for the formation of compounds 3a and 3b [16]. 
The protected hydroxymate derivatives (compounds 5 and 6) are 
coupled with the protected biscatechol-containing spermidine 
derivative 7. 
produce compounds 4a and 4b (Fig. 3). Indeed, removal of 
the t-butoxycarbonyl (Boc) protecting groups from com- 
pounds 5 and 6 with trifluoroacetic acid (TFA) gave the 
corresponding amine salts, which were separately coupled 
to compound 7 using l-(3-dimethylaminopropyl)-3-ethyl- 
carbodiimide (EDC), N-hydroxybenzotriazole (HOBT) 
and triethylamine to give compounds 9a and 9b. Similarly, 
removal of the carbobenzyloxy (Cbz) group (achieved 
using HBr/HOAc) from our previously described 6-N- 
hydroxy-L-ornithine derivatives 10 and 11 [9,17] and 
reprotection with the Boc group gave compounds 12 and 
13. Subsequent coupling with the p-nitrobenzyl (pNB) 
ester of Lorabid@, generated from Boc precursor 14, pro- 
duced protected hydroxamate conjugates 8a and 8b. Brief 
treatment of these conjugates with TFA to remove the N- 
terminal Boc groups was followed by separate reaction 
with the preformed N-hydroxysuccinimide (NHS) ester of 
compound 7 to provide protected conjugates 15a and 15b. 
Deprotection of compounds 9a,b and 15a,b under carefully 
selected conditions (see Materials and methods), gave 
fully deprotected conjugates 3a,b and 4a,b, respectively, in 
near-quantitative yield. 
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Biological studies 
Several assays of bacterial inhibition by conjugates 3a, 
3b, 4a and 4b were performed (Tables l-3). Previous 
studies of siderophore-antibiotic conjugates, using only the 
standard broth or agar dilution assays to determine the 
minimum inhibitory concentrations (MICs), were found to 
be misleading, as resistant mutants can develop and prolif- 
erate even though most of the population is sensitive to the 
drug [13]. We therefore performed agar diffusion assays of 
compounds 3a and 3b with select microbes. These studies 
suggested that compound 3b, containing the important 
phenylglycyl side chain of Lorabid@, was a more effective 
growth inhibitor than compound 3a. Not surprisingly, in 
the preliminary antibiotic susceptibility tests performed 
by serial dilutions in agar (Table l), compound 3a dis- 
played moderate activity against some Gram-positive and 
Gram-negative bacteria. Compound 3b, however, dis- 
played only mild antibacterial activity against some Gram- 
positive and Gram-negative species; and showed out- 
standing activity against Acinetobacter (MIC = 0.03 pg ml-‘, 
whereas MIC = 64 pg ml-’ for Lorabid@ itself). The MIC 
data determined by the standard agar dilution method for 
compounds 4a and 4b also appeared disappointing for most 
organisms tested, with essentially no activity against Gram- 
positive bacteria and only slight activity against Gram- 
negative strains, although 4a appeared the more effective 
of the two. The activities of compounds 3a, 3b and 4a were 
increased when they were tested in the presence of sulbac- 
tam, a B-lactamase inhibitor [18]. Growth inhibition of 
Esdwichia co& and Pseudomonas aemginosa wildtype strains 
(DCO, K799/W7T) and mutants with diminished permeabil- 
ity barriers (DC& K799/61), (Table 2) indicates that pene- 
tration of the intact outer membrane is not sufficient to 
reach full target activity. As described earlier [14], MIC 
determinations using standard dilution assays do not differ- 
entiate growth of the parent strain from selection and 
growth of mutants lacking specific siderophore receptors 
(thus giving misleadingly high MIC values). We therefore 
performed more detailed kinetic growth studies in broth 
with the B-lactam hypersensitive E. co& strain X580 [14]. 
Conjugates 3a,b and 4a,b each induced significant inhibi- 
tory effects, as microbial growth was significantly delayed 
compared to the control (data not shown). The bacteria 
that eventually did grow were separately incubated again 
in the presence of each of the test compounds. No delay of 
growth relative to the control was observed in this reinocu- 
lation experiment. In our previous experiments with 
siderophore-antibiotic conjugates [13,14] growth of the 
wild-type organism was completely inhibited until selec- 
tion of resistant mutants from the parent E. colZ strain 
occurred. As noted above, the resulting mutants are proba- 
bly deficient in a specific form of iron transport, since 
growth was thereafter observed in the presence of the 
same conjugates that inhibit growth of the original organ- 
ism, but not in the presence of other conjugates (see 
below). Similarly, the mutants that are resistant to the 
mixed-l&and conjugates are presumably deficient in one or 
more iron-transport systems. We therefore undertook a pre- 
liminary characterization of these mutants. 
We previously found [13] that iron-transport-deficient 
mutants selected from previous exposure to siderophore- 
antibiotic conjugates such as compounds 1 and 2 were 
greatly impaired in their ability to grow in mammals. This 
was presumably because they had a decreased ability to 
assimilate iron, even though they were deficient in only 
one of several siderophore outer membrane receptors. The 
new mixed-ligand conjugates would be expected to be 
taken up by more than one receptor, indicating that 
mutants unable to recognize the conjugates might be 
missing more than one siderophore receptor and be espe- 
cially prone to iron starvation under physiological condi- 
tions. Compounds 3a and 3b were tested for their ability to 
inhibit the growth of mutants previously isolated from the 
exposure of E. coli strain X580 to catechol conjugate 2, 
which had been shown to lack the Cir protein [ 131 (Cir and 
Fiu are the two proteins in E. co/i known to recognize and 
initiate the uptake of iron complexes of the monocate- 
cholic enterochelin (enterobactin) precursor dihydroxy- 
benzoic acid and the enterochelin (enterobactin) degra- 
dation product dihydroxybenzoylserine [ 191). Both 3a and 
3b delayed the growth of the Cir mutants relative to the 
control; the delay period was similar to that observed with 
unselected E. co& X580. This suggested that these com- 
pounds either do not exclusively use the Cir protein for 
transport, or do not use the Cir protein at all. Incubation 
with compounds 4a and 4b gave little change relative to 
the growth of the control, perhaps indicating that these 
conjugates do require the Cir protein for transport. 
The mixed-ligand complexes (either alone or as the iron 
complex) were next tested for inhibition of the growth 
of mutants that had been previously isolated from the 
exposure of E. co/i X580 to hydroxamate conjugate 1, 
and which had been shown to lack the outer membrane 
triornithylhydroxamate receptor protein (FhuA) 1131. 
Growth was significantly inhibited by compounds 3b and 
4a, again suggesting that these conjugates either do not 
require just FhuA for transport or do not use FhuA at all. 
The effect of compound 4b on this mutant was less 
dramatic. Repetition of the growth inhibition/delay 
studies with E. coli X580 in the presence of 10 pM of one 
of the mixed-ligand conjugates and EDDA (ethylenedi- 
amine bis(o-hydroxyphenyl)acetic acid, used to simulate 
an iron-deficient medium similar to mammalian serum) 
resulted in an extension of the growth delay caused by 
compound 3a, and complete inhibition of growth in the 
presence of 3b, 4a or 4b. These results suggested that 
conjugates 3b and 4a may use different receptor transport 
systems from the original conjugates 1 and 2, either 
instead of or in addition to the original system, whereas 
compound 4b might not be as versatile. The enhanced 
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effect of the conjugates on inhibition of growth in the 
presence of EDDA (iron limited conditions) might also be 
due to the full expression of the siderophore transport 
systems in this severely iron-limited medium. Indeed, 
further studies with previously selected and characterized 
TonB mutants as well as Cir and Fiu single and double 
mutants from different strains of E. col’i (Table 3) indicate 
that the activities of all four conjugates (3a, 3b, 4a and 4b) 
are dependent on the iron recognition and transport pro- 
teins. The generally higher activity of compound 3b 
allowed us to determine that it shows a clear preference 
for Fiu over Cir. Similar preferences have been noted for 
compounds 3a and 4a (U. Moellmann and R. Reissbrodt, 
personal communication). 
Additional studies with a variety of organisms have been 
performed that confirm the versatility of the new mixed 
ligand conjugates, which will be reported elsewhere [ZO]. 
In general, the inhibitory activity of the conjugates is asso- 
ciated with the ability of the tested bacteria to use the 
individual siderophore portion of the molecules for 
growth promotion in tests excluding the antibiotic compo- 
nent. Assays of mixed ligand conjugates with a variety of 
mutants lacking one or more siderophore outer membrane 
receptor or transport proteins also confirm the suggestion 
from our work that in many cases these new conjugates 
can use more than one iron-assimilation pathway. Interest- 
ingly, growth of some microbes is inhibited by either the 
siderophore components alone or the corresponding con- 
jugates even if the microbe does not recognize or use the 
relevant siderophore. In these cases, the inhibitory effect 
may be due to the ability of the siderophore component to 
withhold iron from certain bacteria, indicating that sidero- 
phore conjugates may in principle have two modes of 
action, inhibiting microbial growth through either active 
transport-mediated drug delivery or iron starvation. 
Significance 
The new mixed-&and siderophore conjugates reported 
here appear to be able to use a variety of active transport 
processes to deliver antibiotics to, and inhibit the growth 
of, parent strains of pathogenic bacteria. Although iron- 
transport-deficient mutants were selected during treat- 
ment, they were iron-starved and, based on precedent 
[13], are expected to be less virulent than the wild type. 
These results suggest that it is possible to design, synthe- 
size and use drug conjugates of siderophores and analogs 
that can be actively transported into microbial cells 
by multiple pathways. An appropriate choice of sidero- 
phore, linker and drug may allow selective targeting and 
destruction of pathogenic organisms, providing a signifi- 
cant therapeutic advantage during the development of 
new antimicrobial agents. By facilitating active trans- 
port, siderophore conjugation may also make drugs to 
which resistance has developed by microbial alteration 
of membrane permeability useful once more. Finally, 
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Synthesis of compounds 4a and 4b [91. The protected forms of 6-N- 
hydroxyornithyl carbacephalosporin, 8a, or the corresponding 
derivative 8b are coupled with compound 7. 
siderophore components themselves or drug conjugates 
may limit microbial vitality by withholding the iron that 
is essential for their growth. 
Materials and methods 
General methods 
Melting points were determined on a Thomas Hoover capillary melting 
point apparatus and were uncorrected. Infrared spectra (IR) were 
recorded on a Perkin-Elmer 1240 spectrophotometer, and were 
obtained either as thin film (neat) or as a KBr pellets. 1H and r3C NMR 
were performed on a General Electric GN-300 spectrometer using 
TMS (CDCI,, CDsOD for ‘H NMR) or solvent CDCI, (CD,OD for 13C 
NMR) as internal standards Dioxane was used as the internal standard 
when D,O was used as the NMR solvent. Peak assignments for 13C 
NMR were made with the assistance of the distortionless enhanced 
polarization transfer (DEPT) pulse program [21]. Mass spectral data (El, 
Cl, FAB) were obtained on a Finnegan MAT Model 8430 spectrometer. 
Silica Gel PF254 (EM Science) was used for flash chromatography. 
Radial chromatography or preparative thin layer chromatography was 
performed with Kiesegel 60 PF254 (EM Science). Elemental analysis 
were performed by M-H-W laboratories. Solvents used were dried and 
purified by standard methods [221. The term ‘dried’ refers to the drying 
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Table 1 
Selected minimum inhibitory concentration of Lorabid@ and mixed-ligand-siderophore conjugates. 
Organism Strain 
Staphylococcus 
aureus 
Staphylococcus 
epidermidis 
Streptococcus 
pneumonia 
Enterococcus sp. 
Klebsiella sp. 
Klebsiella sp. 
Enterobacter aerogenes 
Enterobacter cloacae 
Salmonella sp. 
Serratia 
Shiqella sonnei 
Xl 
x41 
x400 
S132 
270 
222 
C203 
PARK 
2041 
X26 
68 
C32 
EB5 
x514 
x99 
NO 
AC1 2 
Lorabid@ 3a 
1 >I 28 
8 >128 
>128 >128 
>128 >128 
4 >128 
4 >128 
0.03 64 
0.25 64 
64 128 128 
0.25 >128 16 
0.5 >128 64 
>128 128 64 
16 128 32 
0.125 128 16 
16 128 64 
2 128 32 
64 128 0.03 
3b 4a 
>128 16 
>128 4 
>128 8 
>128 4 
>128 2 
>128 32 
16 32 
32 64 
64 
>128 
>128 
>128 
>128 
>128 
128 
128 
128 
4b 
>128 
>128 
>128 
>128 
>128 
>128 
4 
64 
>128 
>I 28 
>128 
>128 
>128 
>128 
128 
128 
128 
Inhibitory concentrations are given as Kg ml-‘. The assay was performed at Eli Lilly and Co. using the standard agar dilution method [21]. 
of an organic layer over anhydrous magnesium or sodium sulfate. All 
reactions were performed under a nitrogen atmosphere. 
4-Nitrobenzyl-7p-[[~[N5-[[N1,N8-bis[2,3-bis(benzyloxy) benzoyfl- 
spermidine-N4-yllsucciny~-N1-(benzyloxy)-l,5-diaminopenty~- 
Iv’-yllsuccinyl] amino]- 1 -carba-3-chloro9-cephem-4-carboxylate 
(compound 9a) 
Boc-protected amine 5 [151 (137 mg, 0.185 mmol) was dissolved in 
dry methylene chloride (1 ml) under nitrogen. The solution was cooled 
to 0 “C (ice bath) and TFA (1 ml) was added slowly. The reaction 
mixture was allowed to warm up to room temperature and further 
stirred for 30 min. The solvent and TFA were removed under a vacuum. 
Traces of TFA were removed by evaporating the oily residue with 
toluene to provide the TFA salt of the deprotected amine of compound 
5 as a yellow oil. The TFA salt and acid 7 (167 mg, 0.190 mmol) were 
dissolved in methylene chloride and triethylamine (19 mg, 0.185 mmol) 
was added. The reaction mixture was stirred for 5 min, cooled (ice 
bath) and additional triethylamine (28 mg, 0.277 mmol) was added 
followed immediately by N-hydroxybenzotriazole (HOBT, 25 mg, 0.185 
mmol) and EDC (53 mg, 0.277 mmol). The solution was warmed 
to room temperature and stirred overnight. The solvent was evap- 
orated and the residue was dissolved in EtOAc. The EtOAc layer 
was washed with 0.5 N HCI, water and brine. Drying and removal of 
Table 2 
Antibacterial activity in the agar diffusion assay against wild type strains and penetration mutants. 
Test organism 3a 3a+S 3b 3b+S 4a 4a+S 4b 
Bacillus sub tilis 12P 16 0 12.5P 0 0 0 
ATCC 6633 
Micrococcus flaws 13 15 0 14 0 0 0 
ATCC 10240 
Salmonella gallinarum 22.5 21.5 0 17.5 0 12.5 0 
ATCC 9184 
Escherichia coli DC Ot 14 16.5 0 13P 0 12P 0 
Escherichia coli DC2+ 23.5 22.5 0 16 0 13.5 0 
Pseudomonas aeruginosa K 799/WT* 12P 11 /POP§ A Al8 15P 17P 0 
Pseudomonas aeruginosa K 799/61# 29 29 13 21 22 24.5 21 
The table shows the size (in mm) of the inhibition zone seen when the 
indicated compounds were present at a concentration of 100 @g 
ml-‘. +S: with 0.5 mM sulbactam. 01 1/2OP indicates a clear inhibition 
zone of 11 mm and an inhibition zone of 20 mm containing many 
resistant colonies., p: colonies within the inhibition zone, P: many 
colonies within the inhibition zone, A: indication of inhibition.The 
samples were applied in 59.~1 aliquots onto g-mm diameter agar 
wells. Strains were reported in the following references: +Richmond 
et al. [24]; *Zimmerman [251. 
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Table 3 
Susceptibility of E. co/i K-12 iron transport and porin mutants in the agar diffusion assay. 
Strain Relevant 
genotype 
3a 3a+S 3b 3b+S 4a 4a+S 4b 
AB 2847 aro B 13 15.5 13P 12.5 12P 11.5 0 
BR 158 ton B 12 11.5 0 0 0 0 0 
H 1443 aro B 17.5 la 13/l 6P 14 13/16P 13.5 0 
H 1728 cir, fiu 0 11.5 0 0 0 0 0 
H la75 fep A, cir 12.5 17 0 14.5 10.5p 14 0 
H 1876 fep A, cir, fiu 0 12P 0 0 0 0 0 
H la77 fep A, fiu 0 13.5 0 11 0 0 0 
H a73 fep A 15 15.5 12.5p/l5P 14 12.5pll5P 13 0 
The zone of inhibition in mm is shown for the indicated compounds at a concentration of 100 kg ml-‘. The samples were applied as 50 ~1 aliquots 
in 9 mm diameter agar wells. +S: with 0.5 mM sulbactam, p: colonies within the inhibition zone, P: many colonies within the inhibition zone. fepA: 
enterochelin receptor [6,20], aroB: blocked aromate (dihydroxybenzoate and enterochelin biosynthesis [19,261. 
solvent afforded a yellow oil that was purified by radial chromatog- 
raphy using MeOHlEtOAc (1 :lO) giving compound 9a (155 mg, 
56 %): IR (neat) 3420-2860 (br), 1775, 1730, 1650, 1520 cm-’ ; ‘H 
NMR (20 O/o DMSO-de in CDCI,) 6 1 .lO-1.90 (m, 14H, CH,), 
2.21-2.75 (m, lOH, CH, including allylic CH,), 2.97 (q, J = 6.0 Hz, 
2H, CH,), 3.05-3.25 (m, 8H, CH,), 3.40-3.60 (m, 2H, CH, obscured 
by solvent peak), 3.87 (m, IH, C8CH,CH), 4.86 (s, 2H, benzylic H), 
5.01 (s, 4H, benzylic H), 5.17 (s, 4H, benzylic H), 5.35-5.45 (m, con- 
taining s at 5.41, benzylic H and C7NH0, 7.05-7.55 (m, 3lH, aro- 
matic H), 7.69 (d, f = 8.48 Hz, 2H, aromatic H), 7.77 (m, lH, NH), 
8.12-8.30 (m, containing d at 8.23, J = 8.5 Hz, total 4H, aromatic H 
and NH), 8.72 (d, J= 8.64 Hz, 1 H, NH); 13C NMR (20 O/o DMSO-de in 
CDCI,) 6 21.4, 23.6, 24.8, 25.9, 26.2, 26.4, 26.5, 27.0, 27.5, 27.8, 
28.4, 28.8, 29.4, 30.7 and 31.0 (allylic), 36.7, 38.5, 38.8, 42.7, 44.6 
(m), 46.7, 52.0, 58.0, 65.9, 70.2, 75.1, 75.2, 75.5, 115.8, 120.7, 
120.9, 123.6, 123.7, 124.2, 127.8, 128.1, 128.3, 128.4, 128.5, 128.7, 
128.8, 129.1, 129.3, 131.0,131.0, 131.3, 134.9,136.8, 137.1, 137.1, 
137.2, 143.0, 145.2, 145.2, 147.2, 151.7, 160.1, 165.6, 165.7, 166.0, 
166.5, 170.8, 171.1, 171.4, 172.0, 172.6; MS (FAB) 1501.7 (MH+). 
Anal. calc’d for Cs,H,,N,O,,CI: C, 67.17; H, 5.97; N, 7.46. Found: C, 
66.98; H, 6.07; N, 7.18. 
7P-[[[[N5-[[N1,N8-bis[2,3-bis(hydroxy)benzoyllspermidine-N4- 
yl]succinyl]-N7-(hydroxy) 1,5-diaminopentyll-N’-yikuccinyll 
amino]-1 -carba-3-chloro-3-cephem-4-carboxylic acid 
(compound 3a) 
Concentrated HCI (13.3 p,I, 0.153 mmol, 300 mol %) of and 15.4 mg 
(20 O/O w/w) of Pd-C was added to a solution of compound 9a (77 mg, 
0.051 mmol) in 1 .O ml of 5 %  aqueous dimethylformamide (DMF; made 
from deionized distilled water and HPLC-grade DMF). This mixture 
was exposed to hydrogen at atmospheric pressure for 36 h. The 
catalyst was removed by filtration. The DMF/water mixture was 
removed by evaporation under high vacuum. The residue was redis- 
solved in MeOH and was evaporated. This process was repeated in 
an attempt to remove any residual DMF. However, the presence of 
traces of solvent was evident (‘H NMR) due to the relatively high affin- 
ity of these compounds towards DMF. The semisolid product was fil- 
tered through a column of Sephadex LH 20 gel (3.0 g; 10 %  
MeOH/EtOAc) to provide compound 3a in 99 %  yield as an amber oil. 
FeCI, positive (purple); IR (TF) 3580-2600 (br), 1765, 1650 cm-‘; 1 H 
NMR (CDsOD) S 1.20-2.05 (m, 14H, CH,), 2.30-3.20 (m, 12 H, 
CH2 including allylic CH, obscured by solvent peak), 3.30-3.50 (m, 
8H, CH,), 3.55-3.75 (m, 2H, CH,), 3.82-3.95 (m, IH, C8CH,CH), 
5.25 (m, 1 H, C7CHNH), 6.72-7.49 (m, 1 OH, ArH and NH); 13C NMR 
(75 MHz, CDsOD, all signals at 25 “C reported) 6 21.0, 23.2, 24.7, 
24.8, 26.0, 27.0, 27.6, 28.4, 29.3, 29.5, 29.7, 29.8, 30.7, 32.0, 32.3 
(allylic), 37.6, 38.0, 39.8, 40.0, 40.2, 44.3, 44.6 (m), 53.7, 59.5, 67.9, 
116.5, 116.6, 118.5, 118.6, 121.0, 123.8, 129.5 (m), 136.1, 138.3, 
147.2, 150.3 (m), 164.4, 167.3, 171.4 (m), 174.3, 174.4, 174.7. MS 
(FAB) m/z 916.3 (MH+). 
4-Nitrobenzyl-7P-[[[[[N5-[[IV’, N8-bis[2,3-bis(benzyloxy)- 
benzoyl]spermidine-N4-yl]succinyll-N1-(benzyloxy)-1,5- 
diaminopentyl]-Ni-yl]succinyl]-o-phenylglycyl]amino]-1 -carba- 
3-chloro-3-cephem-4-carboxylate (compound 9b) 
Protected conjugate 9b was obtained from compound 6 as an oil in 
64 o/, yield in the same manner as 9a was obtained from compound 5. 
IR (neat) 3420-2860 (br), 1775, 1730, 1650, 1520 cm-‘; ‘H NMR 
(20 O/o DMSO-de in CDCI,) 6 1 .l l-l.71 (m, 14H, CH,), 2.22-2.76 
(m, lOH, CH, including allylic CH,), 2.95 (q, J = 6.0 Hz, 2H, CH,), 
3.04-3.24 (m, 8H, CH,), 3.46-3.60 (m, 2H, CH,), 3.81 (m, lH, 
C8CH,CH), 4.84 (s, 2H, benzylic H), 5.00 (s, 4H, benzylic H), 5.16 (s, 
4H, benzylic H), 5.35-5.45 (m, containing s at 5.40, benzylic H and 
C7NHCH), 5.52 (d, J= 7.64 Hz, lH, benzylic H), 7.05-7.53 (m, 36H, 
aromatic H), 7.68 (d, J= 8.61 Hz, 2H, aromatic H), 7.75 (m, lH, NH), 
8.12-8.25 (m, containing d at 8.22, J = 8.71 Hz, total 4H, aromatic H 
and NH), 8.68 (d, J=7.39 Hz, lH, NH), 9.15 (d,J=8.82 Hz, lH, NH); 
13C NMR (20 O/O DMSO-de in CDCI,) 6 21 .l, 23.6, 24.8, 25.9, 26.2, 
26.4, 26.5, 27.2, 27.5, 27.8, 28.4, 28.8, 29.5, 30.6 and 30.9 (allylic), 
36.7, 38.5, 38.8, 42.7, 44.6 (m), 46.7, 52.0, 56.6, 57.7, 65.8, 70.2, 
75.1, 75.2, 75.5, 115.8, 120.7, 120.7, 120.9, 122.8, 123.5, 123.7, 
124.2, 127.3, 127.8, 128.0, 128.2, 128.2, 128.3, 128.5, 128.7, 128.8, 
129.0, 129.3, 131.0, 131.0, 131.1, 131.3, 134.9, 136.8, 137.1, 137.1, 
137.2, 143.0, 145.2, 145.2, 147.2, 151.6, 160.0, 165.5, 165.7, 165.6, 
165.8, 165.9, 170.7, 170.7, 171.1, 171.3, 171.5, 174.6; MS (FAB) m/z 
1501.7 (MH+). Anal. calc’d for C,,Hs,N,O,,CI: C, 67.57; H, 5.92; N, 
7.71. Found: C, 67.47; H, 6.06; N, 7.49. 
7P-[[[N5-[[N1,Ns-bis[2,3-bis(Hydroxy)benzoyllspermidine- 
N~-yl]succinyl]-N1-(hydroxy)-1,5-diaminopen~ll-N1-y~l- 
succinyl~-D-phenylglycy/]amino]-I-carba-3-chloro-3-cephem-4- 
carboxylic acid (compound 3b) 
Hydrogenation of compound 9b was carried out using the same condi- 
tions as for 9a to furnish compound 3b in 99 %  yield as a light amber 
oil: FeCI, positive (purple); IR (neat) 3560-2500 (br), 1760, 1650 cm-‘; 
IH NMR (CD,OD) 6 1.20-2.00 (m, 14H, CH,), 2.30-3.15 (m, 12H, 
CH, including allylic CH, obscured by solvent peak), 3.25-3.45 (m, 8H, 
CH,), 3.50-3.75 (m, 2H, CH,), 3.80-3.90 (m, 1 H, CaCH,CH), 
5.30-5.50 (m, 2H, benzylic CH and C7CHNH), 6.65-7.50 (m, 15H, ArH 
and NH); 13C NMR (75 MHz, CD,OD, all signals at 25 “C reported) 
6 20.9, 22.8, 24.6, 24.8, 26.0, 27.0, 27.6, 28.4, 29.3, 29.5, 29.8, 29.8, 
31.1, 32.0, 32.3 (allylic), 37.6, 37.9, 39.8, 40.0, 40.2, 44.3, 46.6 (m), 
53.8, 59.3, 59.5, 67.9, 116.5, 116.6, 118.5, 118.6, 121 .o, 123.9, 129.8 
Research Paper Iron transport-mediated drug delivery Ghosh et al. 1017 
(m), 135.9, 138.1, 140.2, 147.2, 150.3 (m), 164.4, 167.4, 171.5 (m), 
174.3, 174.4, 174.6, 175.2. MS (FAB) m/z 1049.4 (MH+); HRMS (FAB) 
calc’d for &He, N,O,sCINa: 1071.3843 (MNa+). Found: 1071.3903. 
N5-Acetyl-N,-(benzyloxy)-N2-(tert-butoxycarbonyl)-L-ornithine 
(compound 12) 
To a solution of compound IO [91 (0.2 g, 0.42 mmol) in 5 ml of anhydrous 
methylene chloride was added a 33 %  solution of HBr in glacial acetic 
acid (5 ml). The resulting solution was stirred for 15 min at room tempera- 
ture. The methylene chloride was evaporated. The residue was diluted 
with H,O (5 ml), and neutralized with solid NaHCO,. The solid residue 
after evaporation of the solvent was dissolved in 10 ml of tetrahydrofuran 
(THF): H,O (1 :I), and the pH of the reaction mixture was maintained at 9. 
To the above, a solution of Boc,O (0.370 g, 1.69 mmol) in THF (3 ml) 
was added dropwise, and stirred overnight at room temperature. The THF 
was evaporated and the residue was extracted with ethyl acetate to 
remove excess Boc,O. The organic layer was washed with water, and the 
combined aqueous layer, after acidification with saturated citric acid solu- 
tion, was extracted repeatedly with ethyl acetate. The organic layer was 
washed with H,O, brine, dried (Na,SO,), and filtered. Evaporation of the 
solvent, and flash chromatography (silica gel) using CHCIs:MeOH:acetic 
acid (9O:lO:l) afforded 12 (140 mg, 86 o/o) as an oil. IR (neat): 3300 (br), 
2980, 1720, 1700, 1660 cm-t; ‘H NMR (CDCI,, 300 MHz) 6 1.39 (s, 
9H), 1.52-1.9 (m, 4H), 2.09 (s, 3H), 3.5-4.3 (m, 3H), 4.80 (s, 2H), 
5.2-6.3 (m, 1 H), 7.36 (s, 5H); 13C NMR (CDCI,) 6 21.2, 22.7, 28.2, 29.7, 
44.6, 53.5, 76.7, 79.2, 128.6, 128.8, 129.1, 134.0, 155.7, 172.9, 178.9; 
MS (Cl, isobutane) m/z 281 (M+l-100). 
4-Nitrobenzyl-7P-[[N5-acetyl-N5-(benzyloxy)-N2-(tert-butoxy- 
carbonyl)-L-ornithyl-o-phenylglycyl~amino~-l-carba-3-chloro-3- 
cephem-4carboxylate (compound 8a) 
N-Boc protected Lorabid”, compound 14 (0.162 g, 0.277 mmol), was 
dissolved in 2 ml of dry methylene chloride under nitrogen. The solution 
was cooled to 0 “C (ice-bath) and 2 ml of TFA was added slowly. The 
reaction mixture was allowed to warm up to room temperature, and 
stirred for 30 min. The solvent and excess TFA were removed under 
reduced pressure. Traces of additional TFA were removed by azeotropic 
evaporation with benzene to provide the TFA salt as a solid. The TFA salt 
was dissolved in dry methylene chloride (6 ml), and dry triethylamine (38 
ml, 0.277 mmol) was added to the solution to neutralize the salt. To the 
above solution, compound 12 (0.105 g, 0.277 mmol) in methylene chlo- 
ride (4 ml) followed by 2-ethoxy-1 -ethoxycarbonyl-1,2-dihydroquinoline 
(EEDQ, 0.089 g, 0.360 mol) was added rapidly. The reaction mixture 
was stirred overnight at room temperature. The volatile components 
were evaporated and the residue was diluted with ethyl acetate (20 ml). 
The organic layers were washed with 0.5 N HCI, water, brine, dried 
(Na,SO,) and filtered. After evaporation of the solvent, the crude com- 
pound was purified by chromatography eluting with 1 :l EtOAc/hexanes 
to provide 0.164 g (70 a/o) of 8a as a foamy solid: mp 140-l 42 “C; IR 
(KBr) 1765, 1625 (br), 1420 cm-’ ; ‘H NMR (CDCI,) 6 1.35-l .45 (m, 
containing s at 1.39, 11 H), 1.50-l .80 (m, 5H), 1.99 (s, 3H), 2.42-2.52 
(m, 2H), 3.40-4.00 (m, 3H), 4.2-4.4 (m, IH), 4.77 (s, 2H), 5.23-5.40 
(m, 3H), 5.73-5.92 (m, 1 H), 7.2-7.45 (m, 1 OH), 7.57 (d, J= 8.4 Hz, 2H), 
7.87 (d, J= 7.5 Hz, lH), 8.15 (d, J=8.7 Hz, 2H), 8.44 (d, J=5.4 Hz, 
1H); 13C NMR (CDCI,) 6 172.5, 172.4, 170.7, 164.6, 159.7, 155.9, 
147.5, 142.2, 137.4, 134.0, 131.6, 129.1, 128.8, 128.7, 128.1, 123.5, 
122.7, 79.7, 76.0, 65.9, 58.5, 56.7, 53.2, 52.3, 43.6, 31.5, 29.3, 28.1, 
23.0, 21.2, 20.1; FAB HRMS Calc’d for CQ,H,,N,O,,CI, 847.3070 
(MH+), found 847.3065. Anal. calc’d for C,,H,,N,O,,CI C, 59.48; H, 
5.71; N, 9.92. Found: C, 59.32; H. 5.61; N, 9.69. 
4-Nitrobenzyl-7P-[[N5-Acetyl-N5-(benzyloxy)-N2-[N1,N8- 
bis[2,3-bis(benzyloxy)benzoyllspermidine-N4-yl]succinyl]-r.- 
ornithyl-n-phenylglycyl]amino]- 1 -carba-3-chloro-3-cephem-4- 
carboxylate (iSa) 
To a solution of compound 8a (0.120 g, 0.141 mmol) in 1 .O ml of anhy- 
drous methylene chloride under nitrogen at 0 “C was added 0.5 ml 
of TFA. The solution was stirred for 30 min, then concentrated under 
reduced pressure. Excess TFA was removed by repeated evaporations 
from benzene. The TFA salt was dissolved in 2 ml of methylene chlo- 
ride, and dry triethylamine (20 ml, 0.141 mmol) was added. A solution 
of the active ester (obtained from overnight stirring of compound 7 
[lo] (0.124 g, 0.141 mmol), with dicyclohexylcarbodiimide (0.034 g, 
0.169 mmol), and N-hydroxysuccinimide (0.019 g, 0.169 mmol)) in dry 
THF under nitrogen was added to the above solution of the free amine, 
and stirred overnight at room temperature. The solvent was removed 
under reduced pressure. The organic residue was diluted with ethyl 
acetate and washed with brine, dried, filtered, and concentrated to 
give a white foam. Compound 15a was isolated by silica gel chromato- 
graphy eluting with 10 %  methanol/ethyl acetate to afford 0.143 g 
(80 O/o) of product as a foamy solid: mp 73-75 “C; IR (KBr) 1765, 
1685-1600, 1425 cm-‘; ‘H NMR (CDCI,) 6 1.1-1.9 (m, 13H),1.98 
(s, 3H), 2.2-2.7 (m, 6H), 2.85-3.30 (m, 8H), 3.5-3.85 (m, 3H), 
4.15-4.45 (m, lH), 4.7-4.75 (m, 2H), 5.0-5.7 (m, 12H), 7.0-7.7 (m, 
38H), 7.9-8.05 (m, 3H), 8.09 (d, J = 9.0 Hz, 2H), 8.45-8.65 (m, 1 H); 
13C NMR (CDCI,) S 173.8, 172.2, 171.6, 171.0, 165.3, 165.3, 165.2, 
160.1, 151.7, 151.7, 151.6, 147.5, 146.7, 146.6, 146.6, 146.3, 142.3, 
142.3, 136.6, 136.3, 136.3, 136.3, 134.2, 131.0, 129.2, 129.1, 
128.9, 128.9, 128.7, 128.6, 128.5, 128.2, 127.7, 127.6, 124.4, 124.4, 
123.6, 123.0 (m), 116.9, 116.8, 116.4, 77.2, 76.3 (m), 71.1, 71.1, 
65.93, 58.5, 57.6, 53.5, 52.6, 52.5, 47.1 1 45.0, 44.7, 42.8, 39.3, 39.0, 
37.0, 36.9, 31.8, 31.6, 28.5, 28.4, 28.3, 27.6, 27.6, 27.5, 27.2, 26.6, 
26.4, 26.0, 24.6, 23.5, 23.4, 21.4, 20.3; FAB HRMS calc’d for 
C,,H,,N,O,,CI, 1606.6378 (MH+), found 1606.6431. Anal. calc’d 
for C,,H,,N,O,,CI: C, 67.22; H, 5.83; N, 7.84. Found: C, 67.12; H, 
6.02; N, 7.66. 
7p-[[N5-acetyl-N5-hydroxy-N2-~[~’,N8-bis[2,3-bis(hydroxy) 
benzoyl]spermidine-N4-yl]succinyl~-~-ornithyl-D-phenylg~cyl] 
amino]-1 -carba-3-chloro-3-cephem-4carboxylic acid 
(compound 4a) 
To a solution of compound 15a (0.09 g, 0.084 mmol) in 1.0 ml of 
HPLC-grade DMF and 50 ml of distilled deionized water was added 
20.8 ~1 of concentrated HCI (300 mol O/o) and 0.018 g of 10 %  palla- 
dium on carbon. The mixture was exposed to hydrogen at atmospheric 
pressure for 42 h. The catalyst was removed by filtration with methanol 
and the solvents were removed under reduced pressure. ‘H NMR 
showed traces of DMF despite attempts to remove it. The product was 
obtained as an amber oil in near quantitative yield: FeCI, positive 
(purple); IR (neat) 3400-2600, 1760 (br), 1700-1610 (br) cm-‘; ‘H 
NMR (CDsOD) 6 1.25-1.85 (m, 13H), 2.02 (br s, 3H), 2.1-2.9 (m, 
obscured by residual DMF, 6H), 3.1-3.8 (m, 11 H), 4.2-4.4 (m, 1 H), 
4.6-5.0 (m, obscured by solvent peak, 2H), 6.7 (m, 1 H), 6.95 (m, 1 H), 
7.15-7.50 (m, 1 lH), 7.95-8.25 (br m, exchangeable); 13C NMR 
(CD,OD) 6 172.8, 171.9, 171.1, 170.9, 168.0, 164.4, 164.3, 163.9, 
163.8, 150.7, 147.5, 139.4, 137.1, 134.0, 131.2, 129.2, 128.5, 128.4, 
121.7, 120.2, 119.4, 119.4, 118.7, 118.7, 118.6, 116.4, 73.8, 67.3, 
58.0, 53.7, 47.9, 45.2, 44.2, 38.0, 37.2, 35.3, 33.7, 32.2 (allylic), 29.3, 
28.7, 27.7, 27.6, 27.3, 25.4, 25.4, 24.5, 21.7. MS (FAB) m/z 1021 
(MH+), 1043 (MNa+), and 1058.4 (MK+). 
N5-acetyl-N5-(benzyloxy)-N2-(tert-butoxycarbonyl)-L-ornithyl- 
N5-ace~l-N5-(benzyloxy)-L-ornithyl-N5-acetyl-N5-(benzyloxy)- 
L-ornithine (compound 13) 
Following the procedure described for the synthesis of compound 12, 
compound 11 (0.2 g, 0.213 mmol) was exposed to a 33 %  solution of 
HBr in glacial acetic acid and after workup gave compound 13 (0.15 g, 
78 %) as an oil. IR (neat): 3300 (brm), 2940-3000 (br), 1720, 
1665 cm-l; ‘H NMR (CDCI,, 300 MHz) 6 1.37 (s, SH), 1.4-l .85 (m, 
12H), 1.97, 2.04, 2.05 (3s 9H), 3.4-3.9 (m, 6H), 4.2-4.6 (m, 3H), 
4.77 (s, 6H), 7.3-7.5 (m, containing s at 7.39, 15H); 13C NMR (CDCI,) 
6 172.8, 155.7, 155.7, 134.3, 134.2, 134.2, 129.3, 129.2, 128.9, 
128.7, 79.4, 77.2, 76.2, 67.9, 55.7, 53.2 (m), 44.7 (m), 30.3 (m), 28.3, 
23.2, 20.3; MS FAB m/z 905 (MH+), 805 (MH+-100). 
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4-Nitrobenzyl-7P-[[N5-acetyl-N5-(benzyloxy)-N2-(tert-butoxy- 
carbonyl)-L-ornithyl-N5-acetyl-N5-(benzyloxy)-L-o~nithyl-N5- 
acetyl-N5-(benzyloxy)-~-ornithyl-ophenylglycyl]amino~-l~ 
carba-3-chloro-3-cephem-4-carboxylate (compound 8b) 
N-BOG protected Lorabid@, compound 14 (0.043 g, 0.0745 mmol) was 
converted to the TFA salt as described earlier. The TFA salt was dis- 
solved in 2 ml of anhydrous methylene chloride, and 28.5 ~1 of dry tri- 
ethylamine was added to the resulting solution. A THF solution of the 
active ester prepared from compound 13 (0.067 g, 0.0745 mmol), 
NHS (0.01 g, 0.0894 mmol), and dicyclohexylcarbodiimide (DCC, 
0.018 g, 0.0894 mmol) was added, and the reaction mixture was 
stirred overnight at room temperature. Workup and purification 
afforded 0.1 g of compound 8b as a foamy solid (0.081 g, 90 o/o): mp 
80-82 “C; IR (KBr) 1770, 1680-1610 cm-l; ‘H NMR (CDCI,) 6 
1.32-1.42 (m, containing s at 1.40, 1 IH), 1.5-1.8 (m, 13H), 1.91 
(s, 3H), 2.04 (s, 3H). 2.06 (s, 3H), 2.45-2.85 (m, 2H), 3.4-4.1 
(m, 7H), 4.2-4.65 (m, 3H), 4.7-4.9 (m, 6H), 5.2-5.65 (m, 6H), 
7.25-7.45 (m, 2H), 7.57 (d, J=8.4 Hz, 2H), 7.65-7.75 (m, lH), 8.16 
(d, J = 8.7 Hz, 2H), 8.35-8.45 (m, 1 H) ; 13C NMR (CDCI,) 6 172.7, 
172.6, 172.3, 172.5, 171.3, 170.7, 164.4, 160.1, 155.5, 147.4, 141.9, 
136.4, 133.4, 129.7, 128.7, 128.5, 128.9, 128.4, 128.0, 127.4, 123.4, 
122.9, 79.3, 77.0, 75.9, 66.0, 58.9, 57.5, 53.6, 52.8, 52.5, 51.5, 48.7, 
43.3, 33.5, 31.2, 29.8, 29.1, 28.0, 27.7, 26.0, 24.6, 23.6, 22.8, 22.8, 
21 .O, 20.2, 19.9; MS (FAB) m/z 1371 (MH+), 1271 (MH+-100). 
4-Nitrobenzyl-7P-[[N5-acetyl-N5-(benzyloxy)-N2-[[N1,N8-bis[2,3- 
bis(benzyloxy)benzoyl]spermidine-N4-yllsuccinyl]-L-ornithyl-N5- 
acetyl-N5-(benzyloxy)-L-ornithyl-N5-acetyl-N5-(benzyloxy)-L- 
ornithyl-n-phenylglycyl]amino]- 1 -carba-3-chloro-3-cephem-4- 
carboxylate (compound 15b) 
Compound 15b was obtained (0.122 g, 74 o/o) from compound 8b 
(0.098 g, 0.076 mmol) and compound 7 (0.067 g, 0.076 mmol) follow- 
ing the same coupling procedure as described for compound 15a: IR 
(KBr) 1765, 1670-l 610 cm-‘. ‘H NMR (CDCI,) 6 1.0-l .85 (m, 21 H), 
1.9-2.0 (m, 9H), 2.06-2.08 (m, 3H), 2.3-2.7 (m, 6H), 3.0-4.9 (m, 
15H), 4.0-4.45 (m, 3H), 4.65-4.85 (m, 6H), 5.0-5.6 (m, 14H), 
7.0-8.4 (m, 54H); 13C NMR (CDCI,) 6 175.9, 175.7, 173.7, 172.5, 
172.2, 172.1, 171.9, 171.7, 171.3, 165.4, 165.2, 165.2, 160.3, 160.3, 
156.9, 151.7, 151.6, 147.6, 146.5, 142.4, 156.9, 151.7, 147.6, 147.6, 
146.7, 146.6, 146.6, 146.5, 142.4, 142.4, 136.3, 129.2, 129.2, 
128.6, 128.2, 127.6, 124.6, 124.4, 123.7, 123.6, 123.0, 122.9, 122.9, 
116.7, 77.2, 76.4, 76.2, 71.1, 66.1, 66.0, 59.5, 58.3, 52.7, 52.7, 52.7, 
51.6, 45.4, 45.3, 44.5, 39.0, 38.1, 36.9, 31.6, 31.5, 29.6, 28.8, 28.8, 
27.8, 27.1, 26.7, 25.5, 24.9, 23.4, 20.4; MS (FAB) m/z 2131 (MH+). 
7P-liN5-Acetyl-N5-hydroxy-N2-[[N’,N8-bist2,3-bis(hydroxy) 
benzoyl] spermidine-N4-yl]succinyl]-L-ornithyl-N5-acetyl-N5- 
(hydroxy)-L-ornithyl-N5-acetyl-N5-(hydroxy)-L-ornithyl-o- 
phenylglycyl]amino]-1-carba-3-chloro-3-cephem-4-carboxylic 
acid (compound 4b) 
Following the procedure described for the synthesis of 4a, a solution of 
15b (0.057 mg, 0.026 mmol) in 1 ml of 5 % aqueous DMF was hydro- 
genated in the presence of 10 O/o PdlC (1 1.5 mg, 20 O/o w/w) and 
6.6 ml (0.078 mmol, 3 equivalents) of concentrated HCI for 24 h. 
Workup provided compound 4b as a light amber semisolid: FeCI, posi- 
tive (purple); IR (neat) 3400-2600, 1760 (br), 1700-l 610 (br) cm-‘; 
tH NMR (CDsOD) 6 0.8-1.0 (m, 2H), 1.05-1.40 (m, 13H), 1.45-1.90 
(m, 6H), 2.00-2.15 (m, QH), 2.4-2.9 (m, obscured by residual DMF), 
3.25-3.65 (m, 15H), 4.6-4.95 (m, obscured by solvent peak), 5.4 (m, 
1 H), 6.7 (m, 1 H), 6.95 (m, 1 H), 7.20-7.50 (m, 11 H), 7.95-8.30 (br m, 
exchangeable); MS (FAB) m/z 1365.51 (MH+), 1387.49 (MNa+). 
Antibiotic agar dilution tests 
Antibiotic MlCs were determined using a standard agar serial dilution 
test in Miller-Hinton medium [23]. lnocula of test organisms were 
adjusted to -1 O5 colony-forming units (CFU) per ml. After strains were 
incubated for 18-20 h at 37 “C, the MlCs were read as the lowest 
dilution of antibiotic allowing no visible growth. 
Bacterial growth inhibition studies 
Growth kinetics in broth: the basic procedures described for assays of 
compounds 1 and 2 were followed [14]. The test compounds were pre- 
pared as 5 mM stock solutions in DMF and were added to sterile Luria 
broth or sterile Luria broth containing EDDA (100 pg ml-‘) to give 1 .O 
or 10 PM final concentration of the conjugates. 10 ~1 of a 24-h-old 
culture of E. co/i X 580 in Luria broth was added per 50 ml of Luria 
broth. The bacteria were added immediately after addition of the conju- 
gates or after preincubation of the test compound in broth for 12 h at 
37 “C. The culture flasks were then shaken at 37 “C at 300 rpm. 
Aliquots were removed every 2 h and the culture turbidity was measured 
at 600 nm. All the assays were performed in duplicate. 
Antibiotic disc diffusion tests 
The ability of bacteria to use individual unconjugated siderophores, or 
the susceptibility of bacteria to siderophore drug conjugates, was 
tested by antibiotic disc diffusion tests under both iron-restricted and 
iron-sufficient conditions. Agar plates containing exactly 20 ml of Miller 
Hinton medium with or without EDDA at 100 kg ml-’ were inoculated 
with a sterile cotton swab dipped in a bacterial suspension in saline 
(-lo8 CFU ml-‘) and used to streak the surface of the plates. Discs 
(6.0 mm) containing 0.04 mmole of each siderophore or siderophore- 
antibiotic conjugate were placed on the surface of agar plates to allow 
growth inhibition or promotion. Alternatively (Tables 2 and 3), Q-mm 
agar wells were cut out of the plate and separately filled with 50 ~.d of 
test solution in a concentration of 100 p,I ml-‘. Plates were incubated 
at 37 “C for 24 h. f. co/i strains DC0 and DC2 (Table 2) were obtained 
from Richmond [24]. Pseudomonas aeruginosa strains K799/WT and 
K 799/61 were obtained from Zimmermann 1251. E. co/i K-1 2 strains 
were kindly provided by K. Hantke, University of TiJbingen, Germany. 
Growth promotion assays of separate siderophore components were 
performed by the procedures described by Reissbrodt [26]. 
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